Dr. Aly-Khan Lalani is joined by Dr. David Braun and Dr. Bradley McGregor for a virtual roundtable discussion about how physicians are navigating the numerous treatment options and management strategies available to patients with advanced renal cell carcinoma (RCC). The discussion includes a review of the biologic pathways involved in RCC, a look at the plethora of new data for first-line and subsequent-line therapies coming out of the ASCO 2021 Annual Meeting, and a discussion on guiding patients through treatment decisions.
In this video, the panel discusses the rationale for targeting different pathways such as VEGF, HIF-2, PI3-kinase, mTOR, PD-1, and CTLA4 in RCC treatment. They also touch on the active surveillance method and what factors to consider when guiding patients through treatment decisions.
Aly-Khan A. Lalani, MD, BSc, has disclosed no relevant financial relationships.
David A. Braun, MD, PhD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Exelixis; LM Education/Exchange Service.
Bradley A. McGregor, MD, has disclosed no relevant financial relationships.